vTv Therapeutics

What vTv Therapeutics does

vTv Therapeutics is a late-stage clinical biopharmaceutical company headquartered in High Point, North Carolina, that develops oral small-molecule drug candidates for diabetes and related chronic diseases. The company's lead asset is cadisegliatin (TTP399), a liver-selective glucokinase activator (GKA) designed to restore the liver's natural role in glucose storage and release; it is being investigated as the first potential oral adjunctive therapy to insulin for people with Type 1 diabetes (T1D), a population of approximately 1.5 million Americans where roughly 75% do not maintain the American Diabetes Association's HbA1c target of less than 7%. Cadisegliatin received FDA Breakthrough Therapy designation in April 2021 and is currently enrolling the Phase 3 CATT1 trial, with enrollment targeted for Q3 2026 and topline data expected in the first half of 2027. Supporting pipeline assets include TTP273, an Nrf2/Bach1 modulator program, the PPAR-delta agonist HPP593 (Mavodelpar), and HPP737, a PDE4 inhibitor whose global rights were licensed to Newsoara Biopharma in February 2026 for $20 million upfront plus up to $115 million in milestones and tiered royalties.

Name

vTv Therapeutics

Legal name

vTv Therapeutics Inc.

Website

https://vtvtherapeutics.com

Company type

Public

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

vTv Therapeutics is a late-stage clinical biopharmaceutical company developing cadisegliatin (TTP399), an oral liver-selective glucokinase activator in Phase 3 development as the first potential oral adjunctive therapy to insulin for Type 1 diabetes.

Ownership category

akta.pro rank

Product category

Diabetes Biopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

AAV Vector Gene Therapy Developers (HLAAACAA)

Keywords

• Diabetes therapeutics
• Small molecule drugs
• Glucokinase activators
• Biopharmaceutical development
• Prescription pharmaceuticals

Headquarters

HQ city

High Point

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Pharmaceutical Product Sales (Future): Revenue from commercializing cadisegliatin and other drug candidates upon regulatory approval. As a late-stage biopharmaceutical company, vTv's primary future revenue stream would be product sales of prescription pharmaceuticals distributed through pharmacy channels.
2. Licensing and Milestone Payments: Revenue from licensing agreements including upfront payments, development milestones, and sales milestones. The company received $20 million upfront from Newsoara for HPP737 global rights, with potential additional milestones of up to $115 million. Previous licensing deals included $25 million from G42 Healthcare and $10 million from CinPax.
3. Royalties on Net Sales: Ongoing royalty payments based on net sales of licensed products. The HPP737 license agreement includes tiered royalties on future sales.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

vTv Therapeutics is a late-stage biopharmaceutical company developing oral, small-molecule drug candidates for diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), an oral liver-selective glucokinase activator currently in a Phase 3 trial as a potential first-in-class adjunctive therapy to insulin for Type 1 diabetes. The company also develops HPP737 (a PDE4 inhibitor licensed to Newsoara), TTP273, an Nrf2/Bach1 program, and a PPAR-delta agonist.

Product overview

vTv Therapeutics is a late-stage biopharmaceutical company developing a portfolio of oral small-molecule drug candidates for diabetes and related chronic diseases. The company's clinical pipeline is led by cadisegliatin (TTP399), an oral liver-selective glucokinase activator in Phase 3 development as an adjunctive therapy to insulin for type 1 diabetes. Supporting candidates include TTP273, Nrf2/Bach1 Program, TTP-RA, and PPAR-δ (HPP593/MAVODELPAR). HPP737, a PDE4 inhibitor, has been licensed to Newsoara Biopharma for global development and commercialization. The company operates as a single-focus pharmaceutical developer rather than a platform-based product company.

Differentiator

Problem solved

Functional benefit

Products and services

• Cadisegliatin (TTP399) Oral liver-selective glucokinase activator being investigated as an adjunctive therapy to insulin for the treatment of Type 1 diabetes; currently in the Phase 3 CATT1 trial with FDA Breakthrough Therapy designation and potential to become the first FDA-approved oral adjunctive therapy to insulin.
• HPP737 (PDE4 inhibitor)

Quantifiable outcome

• 0.3% statistically significant reduction in HbA1c (p=0.0017) in 12-week SimpliciT1 Phase 2 trial (n=81)
• +4 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• Newsoara Biopharma Co. Ltd.coreOEM/ Whitelabel/ Licensing Partner · 1 February 2026Expanded license agreement granting Newsoara Biopharma exclusive worldwide rights to develop and commercialize the PDE4 inhibitor HPP737. vTv received a $20 million upfront payment in February 2026, with potential development milestones of up to $50 million, sales milestones of up to $65 million, and tiered royalties on net sales. The prior regional license agreement (May 2018) had become void in June 2025, and this amendment establishes a global collaboration.
• M42's Insights Research Organization & Solutions (IROS)coreStrategic or Co-development Partner · 18 December 2025Collaboration with M42's IROS to conduct a Phase 2 clinical trial evaluating cadisegliatin as adjunctive therapy to insulin for Type 2 diabetes. The trial will enroll approximately 300 patients across the UAE, Jordan, and Tunisia, with first patient visit expected in Q1 2026. Under the collaboration, vTv serves as regulatory sponsor while M42 funds the study.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Zealand Pharma: Clinical-stage biopharmaceutical company developing peptide-based therapeutics for diabetes and metabolic diseases, sharing similar development-stage dynamics, public-company status, and therapeutic area focus.
• MannKind Corporation: Public biopharmaceutical company focused on diabetes therapeutics with commercialized inhaled insulin (Afrezza) and endocrine pipeline, directly comparable in therapeutic area and stage of commercialization.
• Provention Bio: Was a T1D-focused biopharmaceutical company developing teplizumab (Tzield) for Type 1 diabetes, acquired by Sanofi in 2023. Highly comparable in T1D focus and late-stage development prior to acquisition.
• Lexicon Pharmaceuticals: Late-stage clinical biopharmaceutical company developing small-molecule drug candidates for diabetes and other metabolic diseases, with comparable market cap profile and clinical-stage business model focused on oral therapies.

Broad incumbents

• Novo Nordisk: Global leader in insulin therapy (NovoLog, Levemir, Tresiba, Fiasp) and diabetes care, setting the standard of care that cadisegliatin would complement as adjunctive therapy if approved.
• Sanofi: Major diabetes player with established insulin portfolio (Lantus, Toujeo) and acquired Provention Bio's T1D asset teplizumab (Tzield), positioning the company as both broad incumbent and direct T1D competitor.
• Eli Lilly and Company: Major diabetes incumbent with leading insulin franchise (Humalog, Humulin, Lyumjev) and incretin therapies (Mounjaro, Trulicity), representing the dominant competitive backdrop and standard of care for any new T1D therapeutic.

Emerging players

• Insulet Corporation: Omnipod tubeless insulin pump and AID system provider, competing in T1D management through device innovation that could reduce demand for pharmacological adjuncts over time.
• Dexcom: Leading continuous glucose monitor manufacturer whose G6/G7 technology addresses T1D glycemic control and hypoglycemia without pharmacology, representing a non-pharmacological competitive approach in the same patient population.
• Tandem Diabetes Care: Insulin pump and automated insulin delivery system manufacturer (t:slim X2, Control-IQ) offering device-based solutions for T1D management, addressing the same patient population via alternative modality.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/vTvTherapeutics
• LinkedInlinkedin.com/company/vtv_therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries1 record

Funding overview

Funding rounds6 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about vTv Therapeutics